A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets cancer cells, while leaving healthy cells unaffected.This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies.

Study Overview

• Status: Completed
• Conditions: Recurrent Adult Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse
• Intervention / Treatment: Drug: GO-203-2c; Drug: GO-203-2c + Decitabine

Detailed Description

• Phase I

  • The maximum tolerated dose (MTD) will be determined in the phase I section of the trial.
  • Patients who fulfill eligibility criteria will be entered into the trial to GO-203-2c.
  • After the screening procedures confirm participation in the research study. The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have acute myeloid leukemia (AML) not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.
  • A subsequent dose escalation will evaluate the combination of GO-203-2c and decitabine.

• Phase II

  • The primary goal is to determine if the combination of the two drugs results in clinical response

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Beth Israel Deaconess Medical Center
    • Boston, Massachusetts, United States, 02115
      • Dana-Farber Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• To be considered eligible for enrollment into this study, all of the following inclusion criteria must be met during the screening period:
• Documented AML by peripheral blood and bone marrow analyses meeting WHO criteria, excluding patients with acute promyelocytic leukemia (APL)
• Patients with AML refractory to primary induction chemotherapy, relapsed disease, or age ≥ 60 and not appropriate for standard cytotoxic therapy due to age, performance status, and/or adverse risk factors according to the treating physician
• Age ≥ 18 years
• Karnofsky performance status ≥ 50% or ECOG performance status 0-2
• Life expectancy ≥ 6 weeks
• Able to understand the investigational nature of this study and to provide written consent to participate in it
• Signed written IRB-approved Informed Consent document

• Adequate hepatic and renal function:

  • serum bilirubin ≤ 1.5 X institutional ULN OR serum direct bilirubin ≤ 2 X institutional ULN
  • serum ALT and AST ≤ 2.5 X institutional ULN
  • serum alkaline phosphatase < 5 X institutional ULN
  • serum creatinine ≤ 2.0 mg/dL
  • corrected calcium level ≥ institutional LLN
• Negative pregnancy test in women of child-bearing potential
• Women and men of child-producing potential must agree to use effective contraceptive methods during the study period (including post-treatment observation period)

Exclusion Criteria:

• A patient will be considered not eligible for enrollment into this study if any of the following criteria are met during the screening period:
• Evidence of leukemic meningitis or other CNS involvement by leukemia
• Uncontrolled or poorly controlled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg) Note: an isolated reading that is not sustained will be permitted.
• Evidence of NYHA Class III or IV cardiac disease, or presence of unstable life-threatening arrhythmia, or history of myocardial infarction during the past 6 months
• Active bacterial, fungal, or viral infection requiring systemic treatment
• Known infection with HIV
• History or major surgery within 4 weeks before the first dose of study treatment, or not recovered from prior surgery
• Exposure to any other investigational agent at any time within 4 weeks before the first dose of study treatment
• Exposure to any other anti-leukemic therapy (except hydroxyurea, see Section 5.5.1) within 2 weeks before the first dose of study treatment
• Pregnant or lactating female
• Unwilling or unable to comply with the requirements of the study protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GO-203-2c; Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle	Drug: GO-203-2c
Experimental: GO-203-2c + Decitabine; Dose escalation will occur for GO-203-2c using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle. Decitabine will be administered at a dose of 20mg/m2 on days 8-12 of a 28-day treatment cycle.	Drug: GO-203-2c; Drug: GO-203-2c + Decitabine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Tolerated Dose of GO-203-2c	Phase I: Maximum Tolerated Dose of GO-203-2c	28 days
Maximum Tolerated Dose of GO-203-2c in combination with decitabine	Phase 1: Maximum Tolerated Dose of GO-203-2c in combination with decitabine	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Tolerability	Number of Participants with Adverse Events as a Measure of Safety and Tolerability	2 years
Determine if therapy results in at least 20% of patients achieving a clinical response	To determine if therapy GO-203-2c in combination with decitabine results in at least 20% of patients achieving a clinical response (blast response, minor response, partial response, or complete response).	2 years

Collaborators and Investigators

• Sponsor: Beth Israel Deaconess Medical Center
• Collaborators: Dana-Farber Cancer Institute
• Investigators: Principal Investigator: David Avigan, MD, Beth Israel Deaconess Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2014
• Primary Completion (Actual): September 1, 2025
• Study Completion (Actual): December 1, 2025

Study Registration Dates

• First Submitted: July 9, 2014
• First Submitted That Met QC Criteria: July 29, 2014
• First Posted (Estimated): July 30, 2014

Study Record Updates

• Last Update Posted (Actual): April 3, 2026
• Last Update Submitted That Met QC Criteria: March 30, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Relapsed acute myeloid leukemia; Refractory acute myeloid leukemia
• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Hematologic Diseases; Leukemia, Myeloid; Leukemia; Hemic and Lymphatic Diseases; Leukemia, Myeloid, Acute; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Nucleic Acids, Nucleotides, and Nucleosides; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Aza Compounds; Nucleosides; Ribonucleosides; Azacitidine; Decitabine
• Other Study ID Numbers: 14-222